Dr Agarwals Eye Hospital growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+18.6%+24.4%+19.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+22.6%+30.1%+21.9%
+26.1%+22.7%+18.2%
+28.3%+17.9%+25.6%
+26.4%+17.9%+25.6%
+25.0%+23.7%+27.1%
+65.2%+33.4%+38.7%
—+5.2%+28.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

DRAGARWQ₹5,299.50

Dr Agarwals Eye Hospital Limited

· Pharma & Health
₹ CrorePeersKMCSHILKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDMcap ₹2,527 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue Growth—+19.2+24.4+18.6
EBITDA Growth—+21.9+30.1+22.6
EBIT Growth—+18.2+22.7+26.1
Net Income Growth—+25.6+17.9+28.3
EPS Growth—+25.6+17.9+26.4
Total Assets Growth—+27.1+23.7+25.0
Total Equity Growth—+38.7+33.4+65.2
Cash from Operations Growth—+28.9+5.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.